Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02

Armata Pharmaceuticals (NYSE: ARMP) announced the FDA has granted Fast Track Designation to AP-SA02, its IV multi-phage candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia (MSSA and MRSA).

Rhea-AI Summary

Armata Pharmaceuticals (NYSE: ARMP) announced the FDA has granted Fast Track Designation to AP-SA02, its IV multi-phage candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia (MSSA and MRSA). Fast Track allows more frequent FDA engagement, rolling BLA review, and potential eligibility for Accelerated Approval and Priority Review.

The company plans to initiate a Phase 3 superiority study anticipated in the second half of 2026 and expects increased FDA interactions during clinical development.

Positive

• FDA granted Fast Track designation for AP-SA02
• Allows rolling BLA submission and review
• Potential eligibility for Accelerated Approval and Priority Review
• Phase 3 superiority study anticipated in H2 2026

Negative

• Fast Track does not guarantee approval or specific timing
• Clinical success required to support Accelerated Approval or Priority Review

Argus May 7 session

+0.99% close to close Open Argus

Details

News Market Reaction – ARMP

On May 7, the day this news came out, ARMP closed 0.99% above the previous close.

Data tracked by StockTitan Argus for the May 7 session.

Key Figures

Phase 3 start target: second half of 2026

Phase 3 start target

second half of 2026

Planned initiation of AP-SA02 Phase 3 superiority study in complicated SAB

Previous Clinical trial Reports

5 past events · Latest: Jan 13

Same Type 5 events

1. Jan 13

   End-of-Phase 2 feedback

   24h Move

   -4.9%

   FDA End-of-Phase 2 response supporting Phase 3 superiority trial for AP-SA02.

2. May 19

   Positive diSArm topline

   24h Move

   +75.6%

   Phase 1b/2a diSArm trial met endpoints with improved outcomes vs BAT.

3. May 19

   DoD funding diSArm

   24h Move

   -15.4%

   Additional $4.65M non-dilutive DoD funding and completed diSArm enrollment.

4. Dec 19

   AP-PA02 Phase 2 data

   24h Move

   +1.5%

   Tailwind Phase 2 showed significant P. aeruginosa reduction and good tolerability.

5. Nov 12

   diSArm enrollment complete

   24h Move

   +22.2%

   Completion of AP-SA02 Phase 1b/2a diSArm enrollment backed by defense funding.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

fast track designation, biologics license application, rolling review, accelerated approval, +4 more

8 terms

fast track designation regulatory

"the FDA has granted Fast Track Designation to AP-SA02"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

biologics license application regulatory

"allows for rolling review of a Biologics License Application ("BLA")"

A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.

rolling review regulatory

"allows for rolling review of a Biologics License Application ("BLA")"

A rolling review is a regulatory process where health authorities examine data on a drug or vaccine as it becomes available instead of waiting for a complete file at the end. For investors, this can speed up the timeline to approval and reduce uncertainty because regulators assess progress in real time—think of reading and approving chapters of a book as they’re finished rather than waiting for the whole manuscript, which can bring forward potential market access and revenue.

accelerated approval regulatory

"may also be eligible for Accelerated Approval and Priority Review"

Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.

priority review regulatory

"eligible for Accelerated Approval and Priority Review if supported by clinical data"

Priority review is a regulatory fast-track that shortens the time an agency spends evaluating a drug, vaccine or medical device application so a decision comes sooner than normal. For investors, it matters because a faster review is like an express lane to market: it can speed revenue potential and reduce regulatory uncertainty, but it does not guarantee approval and still requires the product to meet safety and effectiveness standards.

bacteremia medical

"adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus"

Bacteremia is the presence of bacteria in the bloodstream, which can be a transient event or the start of a serious infection. For investors, it matters because it influences demand for diagnostics, antibiotics, medical devices and hospital care, can change clinical trial outcomes or regulatory decisions, and may affect healthcare costs and company revenues much like a leak in a building’s pipes signals the need for immediate repairs and long‑term maintenance.

methicillin-sensitive s. aureus medical

"bacteremia caused by methicillin-sensitive S. aureus ("MSSA")"

A common type of bacteria, methicillin-sensitive Staphylococcus aureus (MSSA) can cause infections ranging from minor skin boils to serious bloodstream or lung infections, and it is treatable with standard antibiotics. Investors care because the prevalence, treatment costs, and antibiotic options for MSSA affect healthcare spending, hospital demand, drug sales and regulatory decisions for new antibiotics or diagnostics—similar to how a common fault in a product line shapes demand for repairs and replacements.

methicillin resistant s. aureus medical

"or methicillin resistant S. aureus ("MRSA")"

Methicillin-resistant Staphylococcus aureus (MRSA) is a type of common bacteria that no longer responds to methicillin and many other standard antibiotics, causing infections that are harder to treat in skin, wounds, bloodstream or surgical sites. Investors care because MRSA can increase demand for new antibiotics, diagnostics, hospital infection-control products and services, and raise healthcare costs, regulatory scrutiny and legal risk—similar to how a stubborn defect can affect companies tied to its solution.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development

Advances AP-SA02 on a faster path to potential approval and patient access

LOS ANGELES, May 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Fast Track Designation to AP-SA02, the Company's intravenously administered Staphylococcus aureus ("S. aureus") multi-phage product candidate, for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus ("MSSA") or methicillin resistant S. aureus ("MRSA").

"We are pleased to receive Fast Track designation from the FDA for AP-SA02, which marks another important milestone for this program and underscores both the seriousness of complicated S. aureus bacteremia ("SAB") and the urgent need for effective new treatment options," said Dr. Deborah Birx, Chief Executive Officer of Armata Pharmaceuticals. "This designation recognizes the potential of AP-SA02 to improve upon current standard of care treatment options for complicated SAB, a common, extremely severe, and often deadly infection, and highlights the strength of Armata's phage platform to deliver differentiated therapies for bacterial infections. As we advance toward the initiation of our Phase 3 superiority study, anticipated to begin in the second half of 2026, we remain focused on executing efficiently and look forward to interacting more frequently with the FDA throughout the clinical development and review process, with the goal of bringing this novel antibacterial therapy to patients as quickly as possible."

Fast Track designation is intended to facilitate the development and expedite the review of investigational therapies that treat serious conditions and fill an unmet medical need. The designation provides for more frequent interactions with the FDA regarding all aspects of a designated drug's clinical development program, supporting a more efficient path to registration. Fast Track designation also allows for rolling review of a Biologics License Application ("BLA"), meaning completed sections may be submitted and reviewed on an ongoing basis rather than waiting for the full application. Additionally, Fast Track-designated programs may also be eligible for Accelerated Approval and Priority Review if supported by clinical data at the time of BLA submission, further supporting a faster path to potential approval and patient access. For more information on the Fast Track designation, visit the FDA's official website.

About AP-SA02
Armata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct treatment of complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive S. aureus (MSSA) or methicillin resistant S. aureus (MRSA). The diSArm study (NCT05184764) was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 in addition to best available antibiotic therapy ("BAT") compared to BAT alone (placebo) for the treatment of adults with complicated S. aureus bacteremia. Positive results from the Phase 2a diSArm study were highlighted in a late-breaking oral presentation at IDWeek 2025™ in October 2025. The Phase 1b/2a clinical development of AP-SA02 was partially supported by a $26.2 million Department of Defense (DoD) award, received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. The Company plans to advance AP-SA02 into a Phase 3 superiority study in complicated S. aureus bacteremia, anticipated to initiate in the second half of 2026.

About Armata Pharmaceuticals, Inc.
Armata is a late clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, S. aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices ("cGMP") manufacturing to support full commercialization.

Forward Looking Statements
This communication contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata's future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata's actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata's development of bacteriophage-based therapies; Armata's planned clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the U.S. Securities and Exchange Commission (the "SEC"), including in Armata's Annual Report on Form 10-K, filed with the SEC on March 25, 2026, and in its subsequent filings with the SEC.

Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Media Contacts:

At Armata:
Pierre Kyme
ir@armatapharma.com
310-665-2928

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-secures-fda-fast-track-designation-for-ap-sa02-302764421.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does FDA Fast Track designation for Armata (ARMP) AP-SA02 mean?

Fast Track means more frequent FDA meetings and interactions to support development. According to the company, it also enables rolling submission of a Biologics License Application and may allow Accelerated Approval or Priority Review if clinical data support it.

When will Armata (ARMP) start the Phase 3 study for AP-SA02?

Armata anticipates initiating a Phase 3 superiority study in the second half of 2026. According to the company, this timing precedes increased FDA engagement under the Fast Track designation during development and review.

How could Fast Track affect AP-SA02’s regulatory review timeline for ARMP?

Fast Track can expedite development through more frequent FDA interactions and rolling BLA review. According to the company, these mechanisms may accelerate the path to potential approval if supporting clinical data are available at BLA submission.

Is AP-SA02 eligible for Accelerated Approval or Priority Review after Fast Track?

AP-SA02 may be eligible for Accelerated Approval or Priority Review if clinical data support such paths. According to the company, Fast Track designation makes these outcomes possible but not guaranteed without adequate trial results.

What condition is AP-SA02 being developed to treat for Armata (ARMP)?

AP-SA02 is being developed as an adjunct intravenous therapy for complicated Staphylococcus aureus bacteremia, including MSSA and MRSA. According to the company, the program targets severe, difficult-to-treat bloodstream infections.